Oveporexton - Takeda
Alternative Names: TAK-861Latest Information Update: 16 Dec 2024
Price :
$50 *
At a glance
- Originator Takeda
- Class Sleep disorder therapies; Small molecules
- Mechanism of Action Orexin receptor type 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Narcolepsy
- Preclinical Idiopathic hypersomnia
Most Recent Events
- 16 Dec 2024 Chemical structure information added.
- 07 Nov 2024 Phase-III clinical trials in Narcolepsy (In adolescents, In adults, In the elderly) in Australia, Belgium, China, France, Italy, South Korea, Poland, Spain (PO) (NCT06505031)
- 13 Sep 2024 Phase-III clinical trials in Narcolepsy (In adolescents, In the elderly, In adults) in Italy (PO) (EUCT2023-508465-32-00)